Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 3/20 | 0.41 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
| ▸ | ADH1A | P07327 | 3/20 | 0.41 |
| ▸ | ADH7 | P40394 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.31 |
| ▸ | CHRNG | P07510 | 3/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.31 |
| ▸ | CHRND | Q07001 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20737115 | 1.00 | ADH1B (0.41) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL220372 | 1.00 | ADH1B (0.41) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7567537 | 0.97 | ADH1B (0.39) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL331741 | 0.86 | — | — | |
| SCHEMBL13866433 | 0.86 | — | — | |
| SCHEMBL14671382 | 0.86 | — | — | |
| SCHEMBL14444141 | 0.83 | — | — | |
| SCHEMBL19914534 | 0.83 | ALDH1A1 (0.35) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL18070254 | 0.83 | — | — | |
| SCHEMBL14444139 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-117126151-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117069713-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069712-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117024420-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3986863-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2012-06-14 | — | — | US | disclosed |
| WO-2009021747-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ADH1B 173/4885ADH1C 228/4885ADH1A 200/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ADH1B 184/4885ADH1C 235/4885ADH1A 199/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | ADH1B 173/4885ADH1C 228/4885ADH1A 200/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ADH1B 173/4885ADH1C 228/4885ADH1A 200/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ADH1B 173/4885ADH1C 228/4885ADH1A 200/4885 |
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, ACVR2B, CPT1B | ADH1B 465/4885ADH1C 632/4885ADH1A 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.